Quipt Home Medical Corp. (QIPT)
NASDAQ: QIPT · IEX Real-Time Price · USD
4.370
+0.030 (0.69%)
At close: Mar 28, 2024, 4:00 PM
4.210
-0.160 (-3.66%)
After-hours: Mar 28, 2024, 6:50 PM EDT
Quipt Home Medical Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Quipt Home Medical stock have an average target of 10.33, with a low estimate of 10 and a high estimate of 11. The average target predicts an increase of 136.38% from the current stock price of 4.37.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 16, 2024.
Analyst Ratings
The average analyst rating for QIPT stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 2 | 2 | 2 | 3 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Raymond James | Raymond James | Buy → Hold Downgrades $10 | Buy → Hold | Downgrades | $10 | +128.83% | Feb 16, 2024 |
Benchmark | Benchmark | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +128.83% | Dec 20, 2023 |
Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +151.72% | Jun 14, 2023 |
Benchmark | Benchmark | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +128.83% | May 17, 2023 |
Benchmark | Benchmark | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +128.83% | Feb 15, 2023 |
Financial Forecast
Revenue This Year
272.84M
from 221.74M
Increased by 23.04%
Revenue Next Year
295.55M
from 272.84M
Increased by 8.32%
EPS This Year
0.03
from -0.07
EPS Next Year
0.13
from 0.03
Increased by 313.33%
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | 288.7M | 310.7M | 409.9M | 545.4M |
Avg | 272.8M | 295.6M | 357.4M | 529.9M |
Low | 252.8M | 271.5M | 304.1M | 509.1M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | 30.2% | 13.9% | 38.7% | 52.6% |
Avg | 23.0% | 8.3% | 20.9% | 48.3% |
Low | 14.0% | -0.5% | 2.9% | 42.5% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | 0.09 | 0.25 | 0.97 | 1.54 |
Avg | 0.03 | 0.13 | 0.47 | 1.49 |
Low | -0.07 | 0.01 | - | 1.43 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | - | 723.5% | 663.8% | 227.6% |
Avg | - | 313.3% | 271.0% | 218.2% |
Low | - | -68.0% | - | 205.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.